Outpatient management of chronic obstructive pulmonary disease

American Journal of the Medical Sciences

Volumn 318, Issue 2, 1999, Pages 79-83

  Owens, Michael W ^a,c   Markewitz, Boaz A ^a   Payne, D Keith ^b  

^a OVERTON BROOKS VA MEDICAL CENTER   (United States)

^b LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^c Department of Internal Medicine   (United States)

Author keywords

Bronchodilators; Chronic obstructive pulmonary disease (COPD); Corticosteroids; Methylxanthines; Smoking cessation

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT;

ANTIBIOTIC THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CONFERENCE PAPER; EXERCISE; HUMAN; HYPOXEMIA; NUTRITION; OUTPATIENT CARE; OXYGEN THERAPY; RESPIRATORY TRACT INFECTION;

EID: 0033499576     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9629(15)40586-5     Document Type: Conference Paper

References (37)

1. Fletcher C, and Peto R. The natural history of chronic airflow obstruction. Br Med J 1977;1:1645-8.
2. Russell MAH, Wilson C, Taylor C, et al. Effects of general practitioners' advice against smoking. Br Med J 1979;2:231-5.
3. Fiore MC, Bailey WC, Cohen SJ, et al. Smoking cessation. Clinical Practice Guideline No. 18. AHCPR publication no. 96-0692. Rockville (MD): Agency for Health Care Policy and Research, Public Health Service, United States Department of Health and Human Resources; 1996.
4. Transdermal Nicotine Study Sroup. Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials. JAMA 1991;266:3133-9.
5. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdennal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996;335:1792-8.
6. Kanford SL, Fiore MC, Jorendy DE, et al. Predicting smoking cessation: who will quit with and without the nicotine patch. JAMA 1994;271:589-94.
7. Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;337:1195-202.
8. Fiebach N, Beckett W. Prevention of respiratory infections in adults: influenza and pneumococcal vaccines. Arch Intern Med 1994;154:2545-57.
9. Berger R, Smith D. Acute postbronchodilator changes in pulmonary function parameters in patients with chronic air-ways obstruction. Chest 1988;93:541-6.
10. Berger R, Smith D. Effects of inhaled metaproterenol and exercise performance in patients with stable "fixed" airway obstruction. Am Rev Respir Dis 1988;138:624-9.
11. Guyatt GH, Townsend M, Pugsley SO, et al. Bronchodilators in chronic airflow limitation: effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis 1987;135:1969-74.
12. Ajewski Z, Popiak B. The relation between permanent administration of atrovent and the dose of steroids in chronic bronchitis [abstract]. Scand J Respir Dis Suppl 1979;103:205.
13. Jilg J. Long-term treatment with SCH 1000 MDI in outpatients with chronic bronchitis [abstract]. Postgrad Med J 1975;51(suppl):7-13.
14. Minette A. The effects of long-term treatment with SCH 1000 MDI. Postgrad Med J 1975;51(suppl):7153-4.
15. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilators on the rate of decline in FEV1. The Lung Health Study. JAMA 1994;272:1497-505.
16. Braun SR, McKenzie WN, Copeland C, et al. A comparison of ipratropium and albuterol in the treatment of chronic obstructive lung disease. Arch Intern Med 1989;149:544-7.
17. Rennard SI, Serby CW, Ghafouri M, et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD: a retrospective analysis of data from seven clinical trials. Chest 1996;110:62-70.
18. Petty TL. In chronic obstructive pulmonary disease a combination of ipratropium and albuterol is more effective than either agent alone - an 85-day multicenter study. Chest 1994;105:1411-9.
19. Karpel JP, Kotch A, Zinny M, et al. A comparison of inhaled ipratropium, oral theophylline plus inhaled β-agonist, and the combination of all three in patients with COPD. Chest 1994;105:1089-94.
20. Ziment I. Pharmacologic therapy of obstructive airway disease. Clin Chest Med 1990;11:461-86.
21. Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 1991;114:216-23.
22. Pauwell R. Mode of action of corticosteroids in asthma and rhinitis. Clin Allergy 1986;16:281-8.
23. Blackwell GJ, Carnuccio R, Rosa M, et al. Macrocortin: a polypeptide causing the anti-phospholipase effect of corticosteroids. Nature 1980;287:147-9.
24. Townley RG, Reeb R, Fitzgibbons T, et al. The effect of corticosteroids on the beta-adrenergic receptors in bronchial smooth muscle. J Allergy 1970;45:118-121.
25. Bork J, Goldschmidt T, Smedegard G, et al. Methylprednisolone acts at the endothelial cell level reducing inflammatory responses. Acta Physiol Scand 1985;123:221-4.
26. Powell LW, Axelsen E. Corticosteroids in liver disease. Studies on the biological conversion of prednisone to prednisolone and plasma protein binding. Gut 1972;13:690-6.
27. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled steroids. Am J Respir Crit Care Med 1998;157:S1-53.
28. Irwin, RS, Curley FJ. The treatment of cough. A comprehensive review. Chest 1991;99:1477-84.
29. Chafouri MA, Patil KD, Kass I. Sputum changes associated with the use of ipratropium bromide. Chest 1987;86:387-93.
30. Petty TL. The national mucolytic study: result of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990;97:75-83.
31. Ziment I. Agents that affect respiratory mucus. Problems Respir Care 1988;1:15-41.
32. Clark SW, Lopez-Vidriero MT, Pavia D, et al. The effect of sodium 2-mercaptoethane sulphonate and hypertonic saline aerosols on bronchial clearance in chronic bronchitis. Br J Clin Pharmacol 1979;7:39-44.
33. Anzueto A, Jubran A, Ohar JA, et al. Effects of aerosolized surfactant in patients with stable chronic bronchitis. JAMA 1997;278:1426-31.
34. Report of the Medical Research Council Working Party. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;1:681-5.
35. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med 1980;93:391-8.
36. Petty TL, Finigan MM. Clinical evaluation of prolonged ambulatory oxygen therapy in chronic airway obstruction. Am J Med 1968;45:242-52.
37. Krop AD, Block AJ, Cohen E. Neuropsychiatric effects of continuous oxygen therapy in chronic obstructive pulmonary disease. Chest 1973;64:317-22.